The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•20 April 2026•

1 min read

Senzime Expands US Hospital Contract, Boosting Recurring Revenue Outlook

Key Facts

1Senzime signed a contract for an additional 65 TetraGraph systems with a leading hospital system in the southeastern US.

Senzime AB has announced a significant expansion of its contract with a major Integrated Delivery Network (IDN) in the southeastern United States, adding 65 TetraGraph systems to the network. This expansion brings the total installed base within the hospital system to over 160 units, reinforcing Senzime's footprint in the US healthcare market. The increased deployment is expected to generate estimated annual recurring revenue (ARR) exceeding SEK 6 million. This rollout is part of a broader strategy to implement quantitative neuromuscular monitoring technology across large-scale healthcare providers. Analysts view this development as a positive indicator of the company's ability to scale within major hospital systems. The secured recurring revenue provides a stable financial foundation for Senzime's continued growth in the medical device sector.